Tuesday, 29 October 2019

BioLargo Spotlight: Cannabusters Finding Traction in Cannabis and Hemp Industry, Increasing Sales with Unmatched Performance


Pumps used for one Cannabusters Install
BioLargo’s distribution partner for the cannabis and hemp industry, Cannabusters, Inc., continues to land new accounts for our odor and VOC control product! We signed a white label distribution agreement with Cannabusters  to sell CupriDyne® Clean to customers in the cannabis and hemp cultivation industry under the brand name “Cannabusters”. Our partner’s investments in marketing and trade shows across North America are clearly paying off, as the product is beginning to gain traction in the market as industry players are recognizing our product as an effective, eco-friendly, and affordable solution to the odor and VOC control problem in the industry. Since we announced the first Cannabusters sales just a few short weeks ago, the number of accounts for the product in the cannabis and hemp industry has grown to seven and counting.

Cannabusters (www.thecannabusters.com) is selling our white label odor and VOC control products  as well as design, construction, and installation services for product delivery systems as needed. The customers love the product because it’s easy to use and it frequently exhibits odor reduction rates of 90%+, while being eco-friendly and non-toxic. This isn’t surprising given the fact that the product has been demonstrated through third-party laboratory testing to reduce odor-causing terpenes by almost 100%. This fact is a key component in Cannabusters’ ongoing marketing campaign targeting large cannabis and hemp cultivators and processors in the US.
Misting ring for Cannabusters dispersal

As you can see in the image to the right, Cannabusters is frequently deployed through misting rings attached to greenhouses’ exhaust fans. This way, the product is misted through the air that leaves the greenhouse, neutralizing the odor of the air leaving the facility.

Rooftop vent equipped with odor elimination system
Odor-No-More President Joseph Provenzano commented on the growing sales of Cannabusters, “Our products are finding traction in the cannabis industry because they work. Cannabusters’ investments in marketing and product positioning throughout the U.S. and Canada are paying off, and we are thankful for their efforts that are yielding results. As sales of our products grow in this market, we will continue to refine our modeling of potential revenues for our white label cannabis and hemp odor and VOC control products.”

Was this blog post helpful, informative, or interesting? Let us know on social media at:
Twitter: @BioLargo


What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.  

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.


Monday, 21 October 2019

BioLargo Spotlight: Clyra Team Convenes Newly Formed Medical Advisory Board at Symposium for Advanced Wound Care (SAWC) to Plan Clinical Trials and Commercial Roll-out of First Product



Last week, executive management of BioLargo’s subsidiary Clyra Medical Technologies met for the first time with the company’s newly formed Medical Advisory Board to discuss clinical trials, refine the company’s strategy for commercialization, and plan for development of additional products. This meeting comes in the wake of Clyra’s recently announced FDA 510(k) approval for its first advanced wound care product, a wound irrigation product based on the company’s proprietary antimicrobial chemistry.

The Medical Advisory Board meeting took place at the Fall 2019 Symposium for Advanced Wound Care (SAWC) in Las Vegas, a leading forum for the advancement of wound care practices and technology now in its 33rd year. The event was attended by thousands of physicians, researchers, scientists, podiatrists, wound care technology experts, and more.

Clyra’s Medical Advisory Board is comprised of over 30 experts, including medical doctors, surgeons, podiatrists, wound care researchers, and medical industry experts. Members of Clyra’s Medical Advisory Board offer Clyra unprecedented insight into the science and business of clinical wound care and provide invaluable counsel to Clyra as it prepares its first product for clinical trials and commercialization following its recent FDA approval.

To see Clyra’s Medical Advisory Board and learn about its members, visit https://www.clyramedical.com/advisoryboard 
Clyra's President Steve Harrison comments on the Medical Advisory Board meeting, “We are pleased that we have been able to attract some of the best and brightest minds in diverse fields relevant to our powerful and innovative wound care products. Our Advisory Board includes world-renowned experts in wound care, infection research, orthopedic surgery, podiatry, medical product development, reimbursement and more. We look forward to a long and productive relationship with these world-class advisors, and we know our Advisory Board will play a big role in the successful commercial rollout of our advanced wound care products. Our first meeting at SAWC was a huge step toward achieving that goal”.





About Clyra Medical Technologies, Inc.
Clyra Medical Technologies, Inc., a subsidiary of BioLargo, Inc., develops best-in-class advanced wound care products designed to promote fast, effective wound healing without sacrificing tissue health or sensitivity. Clyra’s first product, a wound irrigation solution, received pre-market approval through FDA 510(k) in September, 2019. The company also owns SkinDiscTM, a revolutionary stem cell therapy product that provides unprecedented wound healing with no documented adverse reactions. Learn more at www.clyramedical.com

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.com) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis Calvert 
President and CEO 
BioLargo, Inc. 
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.


Thursday, 10 October 2019

Proactive investors interview: BioLargo reaches 'critical mass' and reports record-breaking revenue ahead of 3Q earnings

Source: Proactive Investors



BioLargo Inc (OTCMKTS:BLGO) CEO Dennis Calvert tells Proactive Investors the California-based technology developer and environmental engineering company has achieved record-breaking quarterly revenue, disclosed in a release ahead of its 3Q earnings report.

Calvert says the growth was driven by huge increases in its Odor-No-More and engineering divisions. The company expects third-quarter revenue of about $500,000, up nearly 90% year-over-year and 23% quarter-over-quarter.

Wednesday, 9 October 2019

BioLargo Breaks New Revenue Records and Pays off Variable Priced Debt


Westminster, CA, October 9, 2019 - BioLargo, Inc. (OTCQB:BLGO) developer of sustainable technologies and a full-service environmental engineering company announced today that in the third quarter of 2019 it has grown its revenues and paid off a series of variable-rate debt instruments, improving its financial condition.

Combined revenues from BioLargo’s operating units during the third quarter of 2019 were approximately $500,000 (total for calendar year 2019 of approximately $1.3 million). These results represent an increase of 88% over the third quarter of 2018, and an increase of  23% over last quarter. 

Both of the company’s commercially active operating units showed increases. Odor-No-More increased revenues by 61% over third-quarter 2018, and 25% over last quarter. The engineering division increased revenues by 300% over third-quarter 2018, and 15% over last quarter. Odor-No-More has shown a steady revenue increase since 2017, as seen in the graph.















Joseph Provenzano, President of Odor-No-More, Inc. commented, “We are now seeing the fruits of our investments in infrastructure and staffing. In just the first week of October, we also have orders in process over $130,000. We intend to further expand our sales and customer support staff to capitalize on our growing success in this market. Notably, we have also secured the first two accounts for our odor and VOC control product in the cannabis and hemp market through our distributor Cannabusters (www.thecannabusters.com), and we believe sales will expand substantially in that emerging segment.”

BioLargo also announced that it has eliminated all of the variable-priced convertible instruments that were eligible for prepayment from its balance sheet, retiring approximately $730,000 in principal. through the payment of $630,000 cash and conversion to stock of an additional $220,000. The company also paid $302,928 in other debt instruments, and another $210,000 in convertible debt will automatically convert to stock in the coming weeks, bringing the total debt reduction to approximately $1,250,000.

President and CEO of BioLargo Dennis P. Calvert commented, “We believe reducing the variable-rate convertible debt will put less short-term selling pressure on our stock and highlights our long-term commitment to building lasting shareholder value. And importantly, business has never been better, as we’ve recently hit several critical commercial milestones.”

Those milestones include:
  • FDA 510(k) clearance for Clyra Medical Technologies’ first product;
  • Preparing for first commercial trial for AOS technology;
  • BioLargo Engineering awarded seven United States Air Force (USAF) base contracts for environmental engineering services with eight more bids in process;
  • BioLargo Engineering won an EPA grant to help solve PFAS contamination, with significant process toward completing a commercial product to address the problem; and
  • BioLargo signed an MOU with a leading wastewater treatment company in South Korea to serve the South Korean wastewater industry with CupriDyne Clean.
Mr. Calvert continued, “Our investments in infrastructure and personnel  are paying off and we are seeing good results from several of our operations. We fully expect the returns on these investments to continue for years to come. We are thankful for the continued support of our long-term investors as we continue to improve our financial condition and build a world-class clean tech company.”


About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert 
President & CEO, BioLargo, Inc. 
888-400-2863
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Tuesday, 1 October 2019

BioLargo, Inc. Announces FDA 510(k) Clearance for Clyra Medical Technologies with The Stock Day Podcast

Source: Newsfile Corp (LINK)

Phoenix, Arizona--(Newsfile Corp. - October 1, 2019) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. CEO Dennis Calvert joined Stock Day host Everett Jolly.
To begin the interview, Jolly noted that BioLargo has experienced a substantial increase in revenue over the past year. Jolly then asked about the company's subsidiary, Clyra Medical Technologies, which recently received its FDA 510(k) clearance. Calvert explained that BioLargo had invested significant capital and time into receiving FDA clearance for its wound irrigation system with Clyra Medical Technologies. "We own about 40% of Clyra Medical Technologies and are also a license holder, so we'll have a royalty on sales," explained Calvert. He then added that this product will lead to the development of at least seven additional products. "This is a multi-billion dollar industry."
Jolly then asked about the potential of the Company's wound irrigation system in comparison with their CupriDyne Clean Industrial Odor Eliminator, which has been highly successful. "When you compare that market to the advanced wound care field, you're talking about a value proposition where we're saving lives and limbs," explained Calvert. "The opportunity to create revenues and profit is astronomically higher."
The conversation then turned to BioLargo's potential partnership with BKT Co. Ltd and the City of Daegu. Calvert shared that BKT Co. Ltd reached out to the company after recognizing mutual goals and values. After forming a closer relationship, both parties believe that a partnership would be extremely beneficial. Calvert also shared that the City of Daegu, South Korea is interested in utilizing the Company's CupriDyne® Clean system for its wastewater treatment.
Jolly then asked for an overview on the BioLargo's varying divisions. Calvert explained that the company focuses on creating innovative and sustainable solutions which can be leveraged to generate revenue all around the world. This is reflected through the BioLargo's diverse set of products, which include solutions in the odor control industry, water treatment industry, and advanced wound care industry.
To close the interview, Calvert shared that the company's technologies are finally starting to prove both its significance and effectiveness. "Now it's all about finding the right partners, making the right moves, making sure we're capitalized properly, and building out some infrastructure," stated Calvert.
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President & CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Stock Day Media
602-441-3474